Thymalin
| Category | Bioregulators |
| Goals | Immune Support |
| Evidence level | Preclinical (plus older Russian clinical reports; little independent replication) |
| Legal status | Research-only — not approved for human use (US) |
| FDA status | Not FDA-approved |
| Half-life | Short; human PK not well characterized |
| Routes | Intramuscular · Subcutaneous |
| CAS / MW / Sequence | Not well established · polypeptide complex · calf-thymus peptide mixture |
| Last reviewed | 2026-06-05 |
In one line
A calf-thymus polypeptide complex (a “Khavinson bioregulator”) used in Russian medicine and studied for immune restoration, especially in aging and immunosuppressed states.
Evidence at a glance
Thymalin has decades of Russian clinical use and reports, but independent replication outside the original research group is limited, and trials predate modern standards. Treat the strongest longevity/mortality claims with caution. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- A polypeptide complex extracted from calf (bovine) thymus, not a single defined synthetic peptide.
- Developed by Khavinson and Morozov in Russia; the broader thymic-peptide / bioregulator tradition.
- Its active dipeptide fraction (Glu-Trp) was later developed separately as the synthetic drug Thymogen.
- Used clinically in Russia for immune restoration (aging, infection, post-surgery, immunosuppression).
- Not FDA-approved; sold as a research chemical. Often paired with Epitalon in longevity protocols.
What Is It
Thymalin is a polypeptide complex isolated from the thymus glands of young calves. It belongs to the Russian “peptide bioregulator” school associated with Vladimir Khavinson and Vyacheslav Morozov. Because it is an extract, it is a mixture of short thymic peptides rather than one defined molecule — which is why it lacks a single clean CAS number / molecular formula. Research identified the dipeptide Glu-Trp as a key active component; that fragment was developed independently as the synthetic peptide Thymogen. Thymalin is positioned as a broad thymic-support agent restoring immune balance.
Thymalin vs Thymogen vs Thymosin alpha-1
Thymalin = calf-thymus peptide complex. Thymogen = synthetic Glu-Trp dipeptide (its minimal active unit). Thymosin Alpha-1 is a different, well-defined 28-amino-acid synthetic thymic peptide. They are related in theme but not identical.
Mechanism of Action
Mechanisms are proposed mainly from animal, cell, and older clinical work:
- Thymic / T-cell modulation (animal/clinical reports) — proposed to support T-cell differentiation and restore immune homeostasis, particularly in age-related immune decline.
- NK-cell and cytokine effects (reported) — modulation of natural-killer activity and cytokine balance.
- Gene-expression / epigenetic regulation (in vitro, bioregulator theory) — Khavinson’s group reports the active dipeptides can bind DNA promoter regions and influence transcription.
- Immunorestoration in stress/aging (clinical reports) — proposed normalization of immune parameters in immunosuppressed patients.
Limitations
Much of the supporting literature is Russian-language and from the originating group. The bioregulator “direct DNA binding” theory is not broadly independently established, and as an extract the exact active composition varies.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Immune restoration (aging, immunosuppression) | Preclinical / older Clinical | Russian clinical reports; limited independent replication |
| Infection / post-surgical recovery | Preclinical / Anecdotal | Reported clinical use; not modern RCT-grade |
| All-cause / cardiovascular mortality reduction | Preclinical / contested Clinical | Long-term Khavinson-group trials; not independently confirmed |
| General “anti-aging” | Anecdotal | Popular claim; outruns rigorous human data |
Reported Dosing
Not medical advice
Protocols as reported in Russian clinical literature and community sources. No FDA-established dose exists. See Reconstitution & Dosing Math and Injection Technique.
| Route | Dose (reported) | Frequency | Cycle |
|---|---|---|---|
| Intramuscular | ~5–10 mg/day | Daily | ~5–10 day course, 1–2×/year |
| Subcutaneous | ~5–10 mg/day | Daily | ~5–10 day course |
Pharmacokinetics
As a mixture of short peptides, Thymalin is expected to have a short circulating half-life (minutes) with rapid peptidase degradation, consistent with the short daily “course” dosing reported. Formal human PK is not well characterized. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Human safety data are limited to mostly older, non–English-language reports; “well tolerated” claims are not modern-trial-grade.
- Anecdotal: injection-site reactions, transient flu-like feelings — not systematically documented.
- Biological-origin concern: as an animal-tissue extract, batch consistency, allergenicity, and contaminant risk are inherent considerations.
- Sourcing risk: research-chemical/extract identity and purity vary widely — see Sourcing and Red Flags & Scams.
- See Side Effects & Risk Management.
Cycling
Reported use is short 5–10 day courses once or twice yearly rather than continuous dosing. No evidence-based cycling standard exists. See Cycling.
Stacks It Appears In
- Khavinson-style longevity protocols pairing Thymalin (immune) with Epitalon (pineal/telomere).
- Discussed alongside NAD+ in broader Longevity & Anti-Aging regimens.
Comparisons
- vs Epitalon — both Khavinson bioregulators; Thymalin targets thymic/immune function, Epitalon targets pineal/telomere themes.
- vs Thymosin Alpha-1 — Thymosin Alpha-1 is a defined 28-aa synthetic thymic peptide with a clearer profile; Thymalin is an extract complex.
Sourcing & Quality
Sold as a lyophilized extract / “research chemical,” so identity, potency, and purity are not guaranteed — and as an animal-derived mixture, batch variability is a real concern. Evaluate before trusting any product: How to Read a CoA, Sourcing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-05.) Not FDA-approved for any use in the US; sold as a research chemical. It has a history of registered medical use in Russia/CIS countries. Status varies by country. See Regulatory & Legal Status.
FAQ
Is Thymalin FDA-approved? No. It is not approved for human use in the US, though it has been used medically in Russia.
Is Thymalin a single peptide? No — it is a polypeptide complex extracted from calf thymus. Its key active fragment (Glu-Trp) was developed separately as Thymogen.
How is it different from Thymosin Alpha-1? Thymosin Alpha-1 is a defined synthetic 28-amino-acid peptide; Thymalin is a less-defined tissue extract.
What is it usually combined with? In Khavinson-group longevity work it is often paired with Epitalon.
References
- Khavinson V.K., Morozov V.G. et al. — thymic peptide bioregulator research (St. Petersburg Institute of Bioregulation and Gerontology).
- “The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity.” PMC (2021). PMC8365293
- Reviews on Khavinson peptide bioregulators (e.g. Bulletin of Experimental Biology and Medicine).
- Comparative thymic-peptide literature distinguishing Thymalin (extract), Thymogen (Glu-Trp), and Thymosin alpha-1.
← Bioregulators · Home Educational information only — not medical advice. See Disclaimer.